Literature DB >> 16208025

Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.

Holenarasipur R Vikram1, Nancy L Havill, Laura M Koeth, John M Boyce.   

Abstract

Daptomycin, a novel cyclic lipopeptide antibiotic, exhibits rapid bactericidal activity in vitro against most clinically relevant gram-positive organisms, including drug-resistant pathogens. Herein we describe a patient in whom methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin was responsible for bacteremia and progressive vertebral osteomyelitis during daptomycin therapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16208025      PMCID： PMC1248502          DOI： 10.1128/JCM.43.10.5384-5387.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Diagn Microbiol Infect Dis       Date:  2000-09       Impact factor: 2.803

2.  Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; George M Eliopoulos; Jeff Alder; Claudie Thauvin Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  A Mangili; I Bica; D R Snydman; D H Hamer
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

4.  Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

5.  In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

Authors:  Laura A Jevitt; Amanda J Smith; Portia P Williams; Patti M Raney; John E McGowan; Fred C Tenover
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

6.  Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.

Authors:  M J Rybak; E M Bailey; K C Lamp; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

7.  Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  K R Fiebelkorn; S A Crawford; M L McElmeel; J H Jorgensen
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

Review 8.  Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

Authors:  Christopher F Carpenter; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2004-03-11       Impact factor: 9.079

9.  Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2004-02-25       Impact factor: 5.790
  9 in total
  18 in total

1.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

2.  Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development.

Authors:  Allison E Aiello; Nicholas B King; B Foxman
Journal:  Am J Public Health       Date:  2006-10-03       Impact factor: 9.308

3.  Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Authors:  Lisa Friedman; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

5.  In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.

Authors:  Olivier Denis; Ariane Deplano; Claire Nonhoff; Marie Hallin; Raf De Ryck; Raymond Vanhoof; Ricardo De Mendonça; Marc J Struelens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

6.  Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.

Authors:  Ilana Lopes Baratella da Cunha Camargo; Hui-Min Neoh; Longzhu Cui; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

Review 7.  Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit.

Authors:  Lee P Skrupky; Scott T Micek; Marin H Kollef
Journal:  Crit Care       Date:  2009-10-08       Impact factor: 9.097

8.  Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  J M Miró; C García-de-la-Mària; Y Armero; D Soy; A Moreno; A del Río; M Almela; M Sarasa; C A Mestres; J M Gatell; M T Jiménez de Anta; F Marco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 9.  Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Authors:  Arnold S Bayer; Tanja Schneider; Hans-Georg Sahl
Journal:  Ann N Y Acad Sci       Date:  2012-12-05       Impact factor: 5.691

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.